2025年2月10日 · PEP (post-exposure prophylaxis) is the use of antiretroviral medication to prevent HIV in a person without HIV who may have been recently exposed to HIV. Exposure typically occurs through sex or sharing syringes (or other injection equipment) with someone who has or might have HIV.

2024年7月22日 · PEP involves administering antiretroviral (ARV) medication after potential HIV exposure to prevent infection. Timely access to PEP is the most crucial factor in PEP effectiveness. PEP is most effective when initiated as soon as possible, ideally within 24 hours and no later than 72 hours after exposure.

What is post-exposure prophylaxis of HIV? HIV PEP is the use of ARV medication to prevent acquisition of HIV after a possible exposure. PEP works by halting viral replication and preventing establishment of a persistent infection during the brief interval after the virus has entered the body but before it becomes an established infection.

2025年3月31日 · PEP refers to the use of HIV medicines to prevent HIV infection within 72 hours (3 days) after a possible exposure. PEP should be used only in emergency situations and is …

2025年1月31日 · HIV PEP, or post-exposure prophylaxis, is a short course of HIV medicines taken very soon after a possible exposure to HIV to prevent the virus from taking hold in your body. You must start it within 72 hours (3 days) after a possible exposure to HIV, or it won’t work. Every hour counts! PEP should be used only in emergency situations.

Post-exposure prophylaxis (PEP) is a short-term treatment that can prevent HIV infection after you might have been exposed to it. PEP involves taking a combination of drugs within 72 hours (preferably sooner) of being exposed, and continuing treatment for 28 days.

2024年10月3日 · First Dose of PEP and Management of the Exposure Site

Adult and adolescent ARV drug dosages for use in PEP Simplified dosing for children of ARV drugs for post-exposure prophylaxis of HIV

PEP is a course of treatment given to someone who’s been exposed to HIV. PEP reduces the risk of becoming infected. PEP doesn’t treat or prevent any other sexually transmitted infections (STIs) like gonorrhoea, chlamydia, HPV (genital warts), herpes or syphilis.

Viraemic HIV-positive or serostatus unknown but presence of HIV risk factors. If source person is on ART, PEP should be started, HIV-VL should be repeated, and, if undetectable, PEP can be stopped.